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Abstract
Cancer antigen 125 (CA125) is a blood biomarker that is routinely used to monitor the progression of human epithelial
ovarian cancer (EOC) and is encoded by MUC16, a member of the mucin gene family. The biological function of CA125/
MUC16 and its potential role in EOC are poorly understood. Here we report the targeted disruption of the of the Muc16
gene in the mouse. To generate Muc16 knockout mice, 6.0 kb was deleted that included the majority of exon 3 and a
portion of intron 3 and replaced with a lacZ reporter cassette. Loss of Muc16 protein expression suggests that Muc16
homozygous mutant mice are null mutants. Muc16 homozygous mutant mice are viable, fertile, and develop normally.
Histological analysis shows that Muc16 homozygous mutant tissues are normal. By the age of 1 year, Muc16 homozygous
mutant mice appear normal. Downregulation of transcripts from another mucin gene (Muc1) was detected in the Muc16
homozygous mutant uterus. Lack of any prominent abnormal phenotype in these Muc16 knockout mice suggests that
CA125/MUC16 is not required for normal development or reproduction. These knockout mice provide a unique platform for
future studies to identify the role of CA125/MUC16 in organ homeostasis and ovarian cancer.
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Introduction
CA125 is a tumor antigen that is routinely used to detect and
monitor the growth of ovarian carcinoma and the outcome of
treatment of ovarian cancer patients [1]. CA125 is a high
molecular weight (.1 M Dalton) mucin-type glycoprotein encod-
ed by the MUC16 gene [2,3,4,5]. MUC16 consists of 22,097
amino acid residues; the gene spans 174 kb on human
chromosome 19. MUC16 contains a large extracellular domain
followed by a tandem repeat domain, a transmembrane domain
and a short cytosolic tail [2,3]. MUC16 is expressed at the apical
surface of coelomic epithelia and its derivatives including epithelial
cells in the Mu¨llerian duct, fallopian tube, endometrium,
endocervix, and mesothelial cells lining the peritoneal and pleural
cavities [6,7,8].
In spite of the utility of CA125 in the clinic, the biological
functions of CA125/MUC16 in normal physiology and ovarian
cancer are still poorly understood. CA125 serum levels are also
elevated in some benign conditions and other carcinomas [1],
raising the possibility that MUC16 might have broad biological
functions. Based on the structural similarity of MUC16 to other
mucins, it is likely that MUC16 may have functions that are
similar to other mucins [reviewed in 9]. MUC16 has been shown
to play roles in mediating both anti-adhesion and cell adhesion,
and in suppressing the immune system. The anti-adhesive
property of MUC16 [10] has been suggested to provide a
protective barrier for the epithelial surface from bacterial
adherence [11] and mechanical injury [12]. Furthermore,
MUC16 in the endometrium of the uterus has been shown to
prevent the attachment of trophoblast during non-receptive status
[13]. In contrast, MUC16 has also been demonstrated to mediate
cell adhesion by binding to other cell surface glycoproteins such as
galectin-1 and mesothelin [14,15]. The binding of MUC16 to
mesothelin is of particular interest because this interaction
implicates a role for MUC16 in dissemination of ovarian cancer
cells to the peritoneal cavity [15]. MUC16 has been shown to
suppress the immune system, by suppressing the activity of natural
killer cells [16,17]. Immune suppressive properties of MUC16,
along with its expression in ovarian cancer cells and fetal
periderm, suggest a role for MUC16 in immune evasion of
ovarian cancer cells from the host immune system and in fetal
tolerance from maternal immune rejection during early pregnancy
[12,16,18]. Other studies suggest roles for MUC16 in endometri-
osis, secretion, and other tissue-specific functions such as in the
upper respiratory tract [12,19,20,21]. However, biological func-
tions of MUC16 in normal physiology as well as in pathological
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conditions such as ovarian cancer still remain unknown. This is
largely due to the lack of in vivo models that disrupt MUC16
expression.
Previously, we characterized the mouse Muc16 homolog by
means of gene structure and expression pattern, demonstrating
that mouse Muc16 is the ortholog of the human MUC16 gene [22].
Here we generated Muc16 mutant mice using gene targeting in
mouse embryonic stem (ES) cells. Muc16 homozygous mutant
mice are normal and fertile, and do not display abnormal
phenotypes by 1 year of age. Lack of abnormal phenotypes in
these Muc16 knockout mice suggests that CA125/MUC16 is not
required for normal development and reproduction. Our mice
provide a valuable in vivo model system to explore MUC16
function in other physiological and pathological conditions such as
ovarian carcinogenesis.
Methods
Disruption of the mouse Muc16 gene in ES cells
The gene structure of the mouse Muc16 gene was determined as
described in a previous study [22]. The targeting vector was
generated from129S7/AB2.2mousebacterial artificial chromosome
(BAC) clones (Sanger Institute, UK; Ensemble ID#s: bMQ-301I10
and bMQ-216K15) containing genomic fragments of the mouse
Muc16 locus.
A 6.1-kb region of Muc16 homology was used. A 4-kb SspF/Bgl1
fragment spanning Muc16 intron 2 and extending 580 bp into
exon 3 was used as a 59 arm of homology, whereas a 2.1-kb BclI/
ScaI fragment spanning Muc16 intron 3 was used as a 39 arm of
homology. The 59 and 39 arms of homology were inserted into a
pBluescript II KS(2) vector (Stratagene, La Jolla, CA) using KpnI/
SalI sites and NotI/SacII sites, respectively.
An ‘IRES-T-lacZ’ reporter cassette, followed by a PgkneobpA
expression cassette flankedby loxP sites [23]was inserted between the
two arms of homology using SalI/NotI sites, replacing most ofMuc16
exon 3 leaving the initial 580-bp of exon 3 intact. The final targeting
vector (Figure 1)was linearizedwith SacII at a unique site in the vector
backbone. 20–25 mg of the linearized targeting vector was
electroporated into 107 cells of the G4 129S6B6F1 hybrid ES cell
line [24] as described [25]. A total of 372 G418-resistant ES cell
clones were initially screened byEcoRI digestion and hybridizedwith
a 59 probe external to the region of homology. Four of the 372 (1.1%)
G418-resistant ES cell clones were identified as correctly targeted
and confirmed using a 39 external probe.
Figure 1. Targeted disruption of the mouse Muc16 gene. (A) Strategy used for Muc16 gene targeting. Organization of the mouse Muc16 gene,
structure of the targeted allele, targeting vector, location of Southern probes, protein region recognized by anti-mouse MUC16 polyclonal antibody,
primers for RT-PCR (6F, 10R; 22F, 27R; 38F, 43R), and genotyping are shown. Bc, BclI; Bg, BglI; BgII, BglII; RI, EcoRI; RV, EcoRV; Sc, ScaI; Ss, SspF, lacZ, IRES-
lacZ-pA; NEO, PgkneobpA; triangle, loxP sites. (B) Southern analysis of genomic DNA isolated from ES cell clones. The sizes of the restriction fragments
detected by 59 and 39 probes are indicated. (C) Southern analysis of genomic DNA isolated from representative pups. +/+, wild type; +/2,
heterozygote; 2/2, homozygous mutant. (D) Targeted deletion of exon 3 region of the mouse Muc16 locus. Loss of exon 3 region is detected by an
internal probe in the homozygous mutants. (E) PCR analysis to determine genotypes. A 414-bp product and a 800-bp product are amplified by the
wild-type primers and the mutant primers, respectively.
doi:10.1371/journal.pone.0004675.g001
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Generation of chimeric mice and germline transmission
of Muc16 mutant allele
Muc16 mutant ES cell clones were microinjected into albino
C57BL/6 (B6) blastocysts and the resulting embryos were
transferred to the uterine horn of 2.5 days post coitus (dpc)
pseudopregnant foster mothers, according to standard protocol
[25]. Chimeric males were crossed with B6 females, and the
agouti-colored offspring were analyzed for germline transmission
of the Muc16 mutant allele. Tail DNA from the agouti pups was
analyzed by Southern blot analysis using 59 and 39 probes to
identify Muc16 heterozygous mutants. We also devised a PCR
genotyping strategy. Primers used for PCR genotyping (Geno_F,
Geno_R, and LacZ_R) are shown in Table 1 and Figure 1A. PCR
conditions were 35 cycles at 95uC for 40 sec, 57uC for 1 min., and
72uC for 1 min. This results in a 414-bp wild-type band and an
800-bp mutant band (Figure 1E). Muc16 heterozygous mutants
were intercrossed to generate Muc16 homozygous mutants. Wild-
type siblings were used as controls. AllMuc16mutant animals were
analyzed on a B6/129 mixed genetic background. All experimen-
tal animals were maintained in accordance with the Institutional
Animal Care and Use Committee of the M.D. Anderson Cancer
Center and the NIH Guide for the Care and Use of Laboratory
animals.
RT-PCR analysis of Muc16 transcripts
Total RNA was extracted from adult tissues of wild-type and
homozygous mutant animals using TrizolH reagent (Life Tech-
nologies, Carlsbad, CA), according to the manufacturer’s
instructions. All procedures of cDNA synthesis and RT-PCR
analysis were performed as described [22]. Briefly, cDNA was
synthesized by reverse transcription (RT) from 1 mg of total RNA
using random hexamers and the SuperScript II first-strand
synthesis system for RT-PCR (Invitrogen, Carlsbad, CA). One
microliter of the first-strand cDNA was used as the template for
the PCR reactions. Primer sequences used in this study are shown
in Table 1 and Supporting Table S1. For Muc16 RT-PCR (6F,
10R; 22F, 27R and 38F, 43R), PCR conditions were 30 cycles at
94uC for 30 sec, 55uC for 45 sec, and 72uC for 1 min. b-actin RT-
PCR was performed as an internal control. RT-PCR of adult
ovary cDNA in the absence of reverse transcriptase served as a
negative control.
Histological analysis and MUC16 immunofluorescence
Generation of rabbit anti-mouse MUC16 polyclonal antibody
was described previously [22]. The region of the MUC16 protein
used to generate the polyclonal antibody is shown in Figure 1.
Tissues were fixed in 4% paraformaldyhyde (PFA) in phosphate-
buffered saline (PBS) at 4uC overnight, then dehydrated,
embedded in paraffin, and sectioned at 5 mm. MUC16 immuno-
fluorescence was performed as described previously [22]. Briefly,
antigen retrieval was performed in 50 mM Tris buffer (pH 9.0) for
20 minutes, then blocking was performed using 10% normal goat
serum diluted with PBS and 0.05% Tween-20 (PBS-T) for 1 hour
at room temperature. The slides were incubated with anti-mouse
MUC16 antibody (1:50) overnight at 4uC and then incubated with
the secondary biotinylated antibody (1:250) (Vector Laboratories,
Inc., Burlingame, CA) for 30 minutes at room temperature. The
slides were next incubated with fluorescein avidin D (1:300)
(Vector Laboratories, Inc., Burlingame, CA) for another 30 min-
utes, washed, counterstained with VECTASHIELD mounting
media with DAPI (Vector Laboratories, Inc., Burlingame, CA),
and examined using fluorescence microscopy.
Real-time reverse transcription-PCR (qRT-PCR)
Total RNA was extracted from adult tissues of Muc16 wild-type
and homozygous mutants using TrizolH reagent (Life Technolo-
gies, Carlsbad, CA). All RNA was treated with DNase I
(Amplification Grade, Invitrogen, Carlsbad, CA). RNA (0.5 mg)
was reverse transcribed using the SuperScript II first-strand
synthesis system for RT-PCR (Invitrogen, Carlsbad, CA) with
random primers. Three microliters of the synthesized cDNA were
mixed with SYBRH Green PCR master mix (Applied Biosystems,
Table 1. Summary of PCR primer sequences, annealing temperatures, and expected product sizes.





6F10R_F 59-GCCCATGTTCAAGAATAGCAGTATTGG-39 56 698 XM_911929
6F10R_R 59-GTAGCAGAGAGGGGCTTGTGGTTG-39 58
22F27R_F 59-CACAACATTACTCAACTGGGTCCC-39 53 855 XM_911929
22F27R_R 59-GTTCACTGTGAACAGCTCCTC-39 52
38F43R_F 59-CCCTTGGTCCAGAATGAATCCC-39 53 574 XM_911929
38F43R_R 59-CACGTGCAGATCTTTCAACTGGTAGG-39 58
Geno_F 59-CAGCATTTCCTATCCAATCACTAACCAG-39 56 414 XM_911929
Geno_R 59-CTAGATTGTATCTGAGCTGTGGTCC-39 55
Geno_F 59-CAGCATTTCCTATCCAATCACTAACCAG-39 56 800 XM_911929
LacZ_R 59-GAAACCAGGCAAAGCGCCATTC-39 56
Muc1_F 59-CCTACCATCCTATGAGTGAATACC-39 51 119 NM_013605
Muc1_R 59-GAGACTGCTACTGCCATTACCTG-39 55
Muc4_F 59-CCTTCACTGATAACCGCTGCTT-39 55 115 NM_080457
Muc4_R 59-GCGGAGGCATTTTCATCCT-39 52
Meso_F 59-GGTCCTGTGGAAGTCCCATCTG-39 56 129 NM_018857
Meso_R 59-CTTGTCTTTGTAGTCTGGGTCTGC-39 57
doi:10.1371/journal.pone.0004675.t001
Disruption of Mouse Muc16 Gene
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Foster city, CA) and qRT-PCR was performed on an ABI PRISM
7900HT (Applied Biosystems, Foster city, CA). The expression
level of each amplicon was calculated by normalizing each cDNA
to glyceraldehyde 3-phosphate dehydrogenase (Gadph) and then
calculating fold change compared with the control. All experi-
ments were repeated three times.
Statistical analysis
Statistical analysis was performed using SAS (SAS Institute Inc.)
or Splus (Insightful Corp.) statistical packages. For the viability
analysis, a chi-square analysis was performed to calculate statistical
significance. For the fertility analysis, the Wilcoxon rank sum test
was used to compare the number of pups per litter between
different genotypes. For the growth data, a mixed model with
repeat approach was fitted to estimate genotype effect on mouse
growth. The Wilcoxon rank sum test was used to compare the
expression levels of Muc1, Muc4 and Mesothelin (Msln) between the
wild-type and the homozygous mutant mice.
Results
Targeted disruption of mouse Muc16 gene
To understand the biological function of CA125/MUC16, we
disrupted the mouse Muc16 gene (Figure 1A). To simultaneously
knockout and mark the Muc16 gene, a 6-kb fragment was deleted
coding for the majority of exon 3 and a portion of intron 3 and
replaced with a IRES-T-lacZpA-loxP-PGKneobpA-loxP reporter
cassette (Figure 1A). This exon was chosen because it showed
sequence homology to exon 1 of human MUC16 that we
confirmed by DNA sequencing. The gene targeting strategy
employed a total of 6.1-kb homology and the arms of homology
were amplified by PCR from 129S7/AB2.2 mouse genomic BAC
clones. Of 372 G418-resistant ES cell clones, 4 clones were
identified as being correctly targeted (Figure 1B). Two different ES
cell clones (1H4, 3C11) were injected into blastocysts indepen-
dently and gave rise to germline-transmitting chimeric males.
Heterozygous offspring were intercrossed to generate homozygous
mutant progeny (Figure 1C). Genotypes of offspring were
confirmed by Southern blotting (Figure 1C). To further demon-
strate that coding exon 3 was disrupted, we designed an internal
probe against the deleted sequence (Figure 1A) and performed
Southern blot analysis. As expected, the predicted exon 3 sequence
was deleted in homozygous mutants (Figure 1D). To accelerate the
genotyping process, we also devised an allele-specific PCR
genotyping strategy, amplifying a 414-bp wild-type band and a
800-bp mutant band (Figure 1E). Both female and male mutant
mice showed the same PCR band patterns. Unfortunately, both
heterozygotes and homozygotes carrying the lacZ allele did not
express b-galactosidase protein or activity by immunofluorescence
or X-gal staining, respectively (data not shown). RT-PCR analysis
showed that Muc16-lacZ chimeric transcripts and downstream lacZ
transcripts were barely or not detected in the mutant mice
(Supporting Text S1, Supporting Figure S1B).
Muc16/MUC16 expression in Muc16 homozygous mutants
To determine the effect on Muc16/MUC16 expression in
homozygous mutants, we analyzed the expression of Muc16
mRNA and protein by RT-PCR and immunofluorescence,
respectively. For RT-PCR, three primer sets were used that can
detect Muc16 transcripts from different subregions of the Muc16
gene (Figure 1A). Muc16 transcripts were not detected in Muc16
homozygous mutant tissues except for the testis that was positive
for all three subregions (Figure 2). Sequence analysis verified that
these homozygous mutant testis-derived RT-PCR fragments were
identical to wild type. Primers used to amplify the region between
exons 38 and 43 yielded a long and short isoform in both wild-type
and homozygous mutant testes (Figure 2). Sequence analysis of
these two isoforms demonstrated that the size differences were
limited to exon 39, suggesting complex RNA processing in this
region (data not shown). A comprehensive RT-PCR analysis of
Muc16 transcripts generated from the testes of Muc16 homozygous
mutants suggests that the expression of exon 3 is eliminated or
significantly reduced, depending on the region of exon 3 examined
(Supporting Text S1, Supporting Figure S1). Thus, no transcripts
containing the entire exon 3 coding region can be generated from
the targeted locus in homozygous mutant testes.
Figure 2. RT-PCR analysis of adult Muc16 wild-type (+/+) and homozygous mutant (2/2) tissues. Primers used for RT-PCR analysis are
shown in Table 1 and Figure 1A. Muc16 amplified products are indicated by arrows. The reactions without reverse transcriptase (2RT) and without
cDNA template (water) serve as negative controls.
doi:10.1371/journal.pone.0004675.g002
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Figure 3. Immunohistochemistry of adult Muc16 wild-type (+/+) and homozygous mutant (2/2) tissues. MUC16 protein (arrows) was
absent in Muc16 2/2 tissues. Asterisk indicates the loss of MUC16 protein in the chief cells in the stomach. OD, oviduct; OV, ovary; ST, stomach; TE,
testis; UT, uterus. Scale bar = 50 mm.
doi:10.1371/journal.pone.0004675.g003
Figure 4. Fertility analysis of Muc16 wild-type (wt) and homozygous mutant (mut) mice. Seven breeding pairs of the indicated genotypes
(M, male; F, female) were mated for 6 months and the numbers of pups were recorded. (A) The median pups per litter is shown with the upper and
lower edges of the boxes equal to the 25% and 75% quartiles. The whiskers indicate 5% and 95% quartiles. Total numbers (N) of litters are shown
under each type of breeding pair. Asterisk indicates a statistical significance in wt F6mut M pairs, compared to wt pairs (p,0.0001). But no statistical
differences were found in mut F6wt M and mut F6mut M pairs, compared to wt pairs (p = 0.33, 0.61). (B) The total accumulated pups for each type of
breeding pair was counted for 6 months.
doi:10.1371/journal.pone.0004675.g004
Disruption of Mouse Muc16 Gene
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We also examined MUC16 expression by immunofluores-
cence. In wild-type tissues, MUC16 protein was detected in the
mesothelia of various organs (Figure 3). In contrast, MUC16
protein was absent in mesothelia as well as other cell types such
as chief cells in the stomach (Figure 3). Although we detected
Muc16 transcripts in homozygous mutant testes by RT-PCR
there was no detectable MUC16 protein detected by immuno-
fluorescence in the mesothelia surrounding the testes (Figure 3).
We conclude that these testicular transcripts are not translated,
at least in the region detected by the polyclonal antibody,
perhaps because of an upstream frameshift in the region of exon
3. Loss of intact Muc16 transcripts and protein in Muc16
homozygous mutant tissues suggests that the Muc16 homozygous
mutants are null mutants. We observed this same absence of
expression in tissues from homozygous mutant parents and their
offspring.
Muc16 homozygous mutant mice are viable, fertile and
grow normally
To determine the phenotype ofMuc16 homozygous mutants, we
intercrossed Muc16 heterozygotes. We obtained wild-type, hetero-
zygous, and homozygous mutants according to the Mendelian
ratio (69 +/+; 137 +/2; 64 2/2). Muc16 homozygous mutants
were grossly normal and showed a normal rate of growth (data not
shown). Because MUC16 is implicated in reproduction, we
monitored the fertility of Muc16 homozygous mutants for 6
months. Both Muc16 homozygous mutant males and females were
fertile (Figure 4). Interestingly, Muc16 homozygous mutant males
bred with wild-type females yielded significantly more progeny in
this breeding assay compared to wild-type males bred with wild-
type females (Figure 4). Muc16 expression in testes is only found in
mesothelia surrounding the gonad [22]. Thus, the reason for this
difference is not clear.
We did not detect any histological differences between wild-type
and homozygous mutant tissues (Figure 5). Up to 1 year, Muc16
homozygous mutant mice were normal both in appearance and
histology (Figure 5). Similar results were obtained for a second
Muc16 lacZ mutant mouse line generated from an independently
targeted ES cell clone (data not shown).
Expression of Muc1, Muc4, and Msln in Muc16
homozygous mutants
One possible explanation why Muc16 homozygous mutants
were normal would be functional compensation by other mucin
genes. To test this idea, we determined the expression level of
Muc1 and Muc4 in Muc16 homozygous uterus and the lung,
respectively. We chose Muc1 and Muc4 because the expression
pattern of these mucin genes overlapped with Muc16 and Muc16
mRNA levels are increased in the lung ofMuc4 knockout mice [26,
Wanda O’Neal, personal communication]. The expression levels
of Muc1 but not Muc4 were significantly downregulated in the
Muc16 homozygous mutant tissues (Figure 6, Muc1 p= 0.01).
These results suggest that MUC16 is required to maintain normal
transcript levels of Muc1. Msln transcript levels were not
significantly different in lung between Muc16 homozygous mutants
and wild-type controls (Figure 6).
Discussion
CA125/MUC16 has served as a very useful serum marker to
monitor the progression of ovarian cancer or response to
treatment. Expression of CA125/MUC16 in multiple normal
tissues and in different pathological and physiological conditions
implies a broad biological role for CA125/MUC16 [1]. This study
reports that Muc16 knockout mice appear normal and do not
display any prominent abnormal phenotypes by 1 year of age. The
phenotype of these Muc16 knockout mice is consistent with that of
other mucin mutant mice. Except for Muc2 knockout mice, Muc1
and Muc4 knockout mice were normal and fertile [27, 28, Wanda
O’Neal, personal communication]. Based on the fact that there are
more than 17 mucin genes, whose expression patterns largely
overlap in different tissues [9], it is possible that functional
redundancy can compensate for the loss of other mucin genes.
Although we did not observe upregulation of Muc1 and Muc4
genes in Muc16 homozygous mutant tissues, it is still possible that
other mucin genes might compensate for Muc16 loss. Another
possible reason why Muc16 homozygous mutant mice are normal
might be the functional compensation by mesothelin in the
mesothelia. Mesothelin is a GPI-linked cell surface glycoprotein,
abundantly expressed in normal mesothelial cells [29], where
MUC16 is also expressed [22]. However, we did not detect any
Figure 5. Histology of Muc16 wild type (+/+) and homozygous
mutant (2/2) tissues. The ovary (A, B), uterus (C, D), lung (E, F), and
testis (G–J) from wild-type (left panel) and homozygous mutant animals
(right panel) were analyzed by H&E staining. Tissues were collected at 3
months (A–B, E–J) and 1 year of age (C, D). Arrowheads indicate
mesothelial cells. Scale bars = 50 mm.
doi:10.1371/journal.pone.0004675.g005
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significant difference in Msln expression levels in Muc16 homozy-
gous mutant lung.
In conclusion, we provide in vivo evidence suggesting that
CA125/MUC16 is not required for normal mouse development
and reproduction. Because Muc16 knockout mice are fertile, they
can be bred with other mouse lines to identify functional
interactions with other genes. In addition, mesothelial cell lines
generated from Muc16 homozygous mutant mice may provide
useful reagents for in vitro studies. These mice will also be a useful
resource for future studies to provide insights into the role of
MUC16 in organ homeostasis and ovarian cancer both in vitro and
in vivo.
Supporting Information
Text S1 RT-PCR analysis of Muc16 homozygous mutant testes.
All of the adult tissues screened by RT-PCR in the Muc16
homozygous mutants were negative for 3 different regions of the
Muc16 locus except for the testes (Figure 2). To understand the
transcripts generated by the Muc16-targeted allele from homozy-
gous mutant testes, we performed RT-PCR, using various sets of
primers (Supporting Table S1, Supporting Figure S1A). A robust
band of the correct size was detected using primers for exons 1 and
3 in wild-type and homozygous mutant testes (Supporting Figure
S1B). This suggests that transcription from the Muc16 targeted
locus to generate mRNA containing exons 1 to 3 appears to be
normal. Using an exon 3 primer present in both the wild-type and
null alleles and an exon 3 primer located within the exon 3 deleted
region of the targeted allele, we detected a positive signal in wild-
type but not homozygous mutant testes (Supporting Figure S1B).
These results support our Southern analysis that indeed the
majority of exon 3 has been deleted by our targeting strategy
(Figure 1D). Thus, the targeted allele cannot generate exon 3-
containing transcripts for the region that was deleted. To
determine if Muc16-lacZ chimeric transcripts were generated,
we used exon 3 and lacZ primers. Muc16-lacZ chimeric
transcripts were detected from the targeted Muc16 allele but the
signal was very weak (Supporting Figure S1B). In addition, using
lacZ primers, lacZ transcripts downstream of the Muc16-lacZ
fusion were undetectable (Supporting Figure S1B). This suggests
that Muc16-lacZ chimeric transcripts may be very unstable,
leading to insufficient production of b-galactosidase for detection
by immunofluorescence and X-gal staining (data not shown). We
also performed RT-PCR using primers for exons 2 and 4 in case
exon 3 which is very large was skipped by alternative splicing,
however, no signal of the predicted size was detected (data not
shown). Even if exon 3 was skipped it would lead to a frameshift
and no MUC16 protein should be generated. We also performed
RT-PCR using primers located in exons 4 and 5, and exons 5 and
6. Both sets of primers amplified the predicted sized bands in both
wild-type and homozygous mutant testes (Supporting Figure S1C).
This suggests that exons 4–6 are being transcribed in the mutant.
The neo gene has its own promoter (Pgk) for expression in mouse
ES cells. It is possible that there may be readthrough of the pA
signal from the neo cassette. Therefore, we also used primers for
neo and exon 4. No signal was detected in homozygous mutant
testes (Supporting Figure S1B). This suggests that the neo pA
signal is functional. Finally, we repeated the RT-PCR using
primers for exons 6 and 10 located downstream of the exon 3
targeted modification. A robust signal was detected in wild-type
testes and a detectable though weaker signal in homozygous
mutant testes (Supporting Figure S1B). These results are similar to
our initial survey of expression (Figure 2). Taken together, these
results suggest that the targeted allele does not express the full
complement of transcripts generated by the wild-type allele. In
addition, no MUC16 protein was detected by immunofluores-
cence using a polyclonal antibody (Figure 3). With respect to the
testis, the targeted modification is clearly a loss-of-function allele.
Formal demonstration that the targeted mutation is a null allele in
the testis is hampered because Muc16 is a very large gene with
many exons [22].
Found at: doi:10.1371/journal.pone.0004675.s001 (0.03 MB
DOC)
Table S1 Summary of PCR primer sequences.
Found at: doi:10.1371/journal.pone.0004675.s002 (0.04 MB
DOC)
Figure S1 RT-PCR analysis of Muc16 locus. (A) Organization
of the mouse Muc16 gene and location of primers used for RT-
PCR analysis (indicated by arrows). (B, C) RT-PCR analysis of
Muc16 expression upstream and downstream of the targeted
region in adult Muc16 wild-type and null testis. Forward (F) and
reverse (R) primers are indicated.
Found at: doi:10.1371/journal.pone.0004675.s003 (2.08 MB TIF)
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Figure 6. Real-time reverse transcription-PCR (qRT-PCR) of Muc1, Muc4, and Msln in Muc16 wild-type (WT) and homozygous mutant
(Mut) tissues. Values are expressed mean +/2 s.e.m. and the mean of the wild type set to ‘‘1’’. Asterisk indicates significant downregulation of Muc1
(p = 0.01) in Muc16 homozygous mutant uterus.
doi:10.1371/journal.pone.0004675.g006
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